Table 2.

Outcome of TP53-mutated myeloid malignancy patients treated with hypomethymating agents. CR: Complete Remission, EFS: Event Free Survival, OS: Overall Survival.

Regimen	Demographics	CR	EFS	OS	References
Azacitidine	20–91 y/o	20–40%	Not available	Median OS: 7 months	[34,35,36,41]
Decitabine	47–90 y/o	30%	Median EFS: 6 months	Median OS: 2.1–7 months	[28,35,37,38,39,40]